IMS 2026 highlights: advances in multiple myeloma treatment and the path towards cure

In this episode of the VJHemOnc podcast, experts discuss key advances in multiple myeloma presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026) in Glasgow, UK. Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, reviews long-term outcomes from the Phase III PERSEUS trial (NCT03710603), while Zachary Avigan, MD, Icahn School of Medicine at Mount Sinai, New York, NY, explores treatment cessation and the potential for cure. Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses combination strategies at first relapse, and Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, examines survival outcomes with teclistamab plus daratumumab in MajesTEC-3 (NCT05083169). Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, reviews ciltacabtagene autoleucel (cilta-cel) outcomes, Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the CERVINO trial (NCT06158841) of etentamig, and Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, explores the evolving role of cereblon E3 ligase modulatory drug (CELMoDs).